IMNM (Immunome, Inc.) Short-Term Debt to Capital

The momentum of Immunome, Inc. (IMNM) is driven by the development of antibodies targeting infections and cancer, as evidenced by data illustrating the price evolution of the stock. The current metric stands at 0.00. The business currently relies on existing capital reserves and test results, as it has yet to generate revenue. High scientific authority and innovator status ensure active support from specialized investors.

This indicator measures the proportion of short-term liabilities (up to one year) relative to equity, allowing for an assessment of liquidity risk and the business's dependence on operational refinancing. By analyzing the ratio of short-term debt to equity, an investor determines the financial stability of Immunome, Inc. (IMNM) during the execution of long-term licensing contracts with pharma behemoths within its B-cell analysis platform.